Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 4

Abatacept in the treatment of rheumatoid arthritis

Authors Edward M Vital, Paul Emery

Published 15 December 2006 Volume 2006:2(4) Pages 365—375

Edward M Vital, Paul Emery
Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, UK
Abstract: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-á) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.
Keywords: abatacept, rheumatoid arthritis, disease-modifying antirheumatic drugs

Download Article [PDF] 

Readers of this article also read:

Unusual case of contralateral Horner's syndrome following stellate-ganglion block: a case report and review of the literature

Amhaz HH, Manders L, Chidiac EJ, Pallekonda V, Chakrabortty S

Local and Regional Anesthesia 2013, 6:31-33

Published Date: 10 October 2013

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

Combating HIV resistance – focus on darunavir

Cécile L Tremblay

Therapeutics and Clinical Risk Management 2008, 4:759-765

Published Date: 8 August 2008

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

F Braido, C Lagasio, IMG Piroddi, I Baiardini, GW Canonica

Therapeutics and Clinical Risk Management 2008, 4:353-361

Published Date: 11 April 2008

A systematic review of infliximab in the treatment of early rheumatoid arthritis

Sophie Martin Du Pan, Cem Gabay, Axel Finckh

Therapeutics and Clinical Risk Management 2007, 3:905-911

Published Date: 15 November 2007

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Shimon Lecht, Simon Haroutiunian, Amnon Hoffman, Philip Lazarovici

Therapeutics and Clinical Risk Management 2007, 3:467-474

Published Date: 15 July 2007

Progress in the development of a cervical cancer vaccine

Ursula Winters, Richard Roden, Henry Kitchener, Peter Stern

Therapeutics and Clinical Risk Management 2006, 2:259-269

Published Date: 15 September 2006